secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silo Pharma, Inc. (SILO)
CIK:        0001514183
Form:       8-K
Filed at:   2025-01-02T23:59:59+00:00
Accession:  0001213900-25-000191
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silo Pharma issues shareholder letter: SPC-15 IND expected 2025, SP-26 animal studies in early 2025
--------------------------------------------------------------------------------

- IND submission for SPC-15 intranasal PTSD treatment expected in 2025; Phase 1 trial to follow upon FDA approval.
- SP-26 ketamine implant for fibromyalgia nearing first animal studies in early 2025; aims for at-home injectable therapeutic.
- Both SPC-15 and SP-26 may qualify for FDA's streamlined 505(b)(2) approval pathway, reducing costs and time.
- Cash on hand and minimal debt provide financial flexibility; no specific financial guidance disclosed.
- Exclusive global license from Columbia University for SPC-15 pre-clinical development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1514183/000121390025000191/0001213900-25-000191-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1514183/000121390025000191/ea0226314-8k_silopharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-000191

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer